Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06186856
Recruiting Observational

Epidemiological Data on Mast Cell Pathologies in France

NCT06186856 · tracked via the Priya Life Science France tracker
Sponsor
Imagine Institute
Phase
Observational
Started
2024-11-01
Last updated
2026-04-22

Condition(s) studied

Mast Cell Disorder

Study summary

Mast cell disorders constitute a heterogeneous group of diseases, including :

* mastocytosis, i.e. cutaneous, indolent and severe forms of the disease, such as aggressive mastocytosis and mast cell leukemia) ;
* mast cell-associated diseases such as mast cell activation syndrome (idiopathic, secondary or clonal), affecting both children and adults.

No epidemiological data are currently available in France.

In France, medical care of mast cell disorders is mainly provided by a rare disease network (CEREMAST), whose CRMR is located at the Necker Enfants Malades hospital in Paris. A total of 20 centers are located throughout France.

Our aim is to use this network to study patients suffering from these diseases. The overall aim of the study is to improve the understanding, diagnosis, prognosis, recognition and management of patients with mastocytosis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Children from birth and adults of any age 2. With one of the following mast cell diseases: * Mastocytoses (cutaneous, systemic and sarcomas) Defined according to the WHO 2016 classification * Mast cell activation syndromes (idiopathic, secondary and clonal) * Other mast cell activation disorders (MCAD-NOS), Defined according to the Vienna classification * Pre-mastocytosis or MMC (1 to 2 criteria according to WHO 2016 classification). 3. Managed in France in a rare disease reference, constitutive or competence center (CEREMAST) with DGOS labelization. Exclusion Criteria: 1\. Opposition of the patient or his/her parents to participation in the study.

Primary outcome measure(s)

  • Epidemiology of mast cell disorders in France assessed by statistics on the prevalence on the various types of mast cell disorders — Data 2010 - 2038
  • Epidemiology of mast cell disorders in France assessed by statistics on the incidence on the various types of mast cell disorders — Data 2010 - 2038

Trial sites (21)

FacilityCityRegionStatus
CHU AMIENS site sud Amiens France Recruiting
Chu Angers Angers France Recruiting
Chu - Besancon Besançon France Recruiting
Chu - Caen Caen France Recruiting
Chu - Clermont Ferrand Clermont-Ferrand France Recruiting
CHU Grenoble Grenoble France Recruiting
Chru Lille Lille France Recruiting
Chu - Limoges Limoges France Recruiting
Hospices Civils de Lyon Lyon France Recruiting
Chu - La Timone - Marseille Marseille France Recruiting
CHU de Montpellier Montpellier France Recruiting
CHU de NANCY Nancy France Recruiting
Chu - Nantes Nantes France Recruiting
Hôpital Universitaire Pitié Salpetrière Paris France Recruiting
Hôpital Necker-Enfants malades Paris France Recruiting
CHU - Poitiers Poitiers France Recruiting
Chu - Rennes Rennes France Recruiting
CHU Réunion sud - Saint Pierre Saint-Pierre France Recruiting
Chru - Strasbourg Strasbourg France Recruiting
CHU Purpan Toulouse France Recruiting
CHU de TOURS Tours France Recruiting

More Imagine Institute trials in France

COVID-19 in PID Survey Recruiting
Automatic Phenotyping of Patients on 2D Photography Recruiting
Evaluation of Socio-professional Inclusion for Young Adults Aged 15-25 Living With a Rare Genetic Disability Recruiting
Mapping Epileptic Networks Using Multimodal Imaging Recruiting
Natural History of Type 1 Interferonopathies: Insights From a European Cohort Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06186856 on ClinicalTrials.gov ↗ ← All trials in France